Profusa To Merge With Privately Held, Commercial-Stage Health Diagnostics And Toxicology Testing Company; Profusa To Issue 19.99% Stake to T
Following the contemplated transaction, the combined company is expected to operate as a public diagnostics company with national CLIA-certified laboratories, recurring revenues from a diversified base of providers serving addiction treatment, pain management, and behavioral health. The Dx Company’s 2025 Net Revenues a